Lord's Mark Industries Limited has achieved a significant regulatory milestone by securing US FDA registration for more than 150 orthopaedic surgical products. The company announced on January 6, 2026, that it has joined the elite group of select Indian companies with such extensive FDA compliance, demonstrating its commitment to quality and global standards.

Manufacturing Excellence and Compliance

All orthopaedic surgical products are manufactured at the company's globally aligned manufacturing facility in Silvassa. The facility operates in compliance with internationally benchmarked production protocols and quality management systems, meeting the stringent regulatory requirements prescribed by the US FDA.

Comprehensive Product Portfolio

The US FDA-listed portfolio includes an extensive range of orthopaedic surgical and rehabilitation products:

Strategic Market Expansion

According to Managing Director Mr. Sachidanand Upadhyay, this milestone reflects the company's regulatory discipline, manufacturing strength, and long-term vision to position India as a trusted source of globally compliant healthcare solutions. The achievement significantly strengthens Lord's Mark Industries' access to highly regulated international markets.

Global Market Access

The FDA registration enhances the company's opportunities across multiple fronts:

• Access to highly regulated international markets including the United States, Latin America, and the Middle East
• Enhanced opportunities for institutional supplies and hospital partnerships
• Export growth facilitation through the company's US-based subsidiary, Lords Mark Global LLC

This regulatory achievement positions Lord's Mark Industries Limited to capitalize on growing demand for quality orthopaedic products in international markets while maintaining compliance with stringent global healthcare standards.

Lord's Mark Industries Limited conducted its Fifth Monitoring Committee meeting on January 03, 2026, through video conferencing under the chairmanship of Erstwhile Resolution Professional Mr. Amit C Poddar. The meeting addressed several critical corporate restructuring matters and strategic initiatives as the company works toward resuming trading on the BSE platform.

Capital Restructuring Progress

The Monitoring Committee reviewed significant progress on implementing the NCLT Order dated July 28, 2025. Key developments in the capital restructuring process include the identification of 4,90,051 equity shares held by former promoters for extinguishment and proportionate reduction of public shareholding to a maximum of 5% per shareholder.

The committee noted approval for a major share allotment as part of the amalgamation process:

The Erstwhile Resolution Professional has maintained constant communication with BSE and SEBI to finalize implementation and resume trading activities.

Rights Issue Approval

The Monitoring Committee unanimously approved a proposal to raise capital through a rights issue, demonstrating strong support for the company's growth plans:

The rights issue will proceed once the company's shares resume trading on the BSE platform, following completion of all regulatory compliances and capital structure updates.

Employee Stock Option Plan Implementation

To support expansion into renal care and medical technology sectors, the committee approved creation of an Employee Stock Option Plan (ESOP). The company has recently entered the renal care business through acquisition of RenalX Healthcare Systems Limited, which developed an AI-based dialysis machine.

The ESOP structure includes:

The company plans to manufacture and sell AI-based dialysis machines, operate dialysis centers across India, and export products internationally. Additionally, the company has developed a remote patient monitoring system with its own data center, receiving significant demand from the United States and Europe.

Financial and Administrative Matters

The committee ratified monitoring period expenses incurred by the Erstwhile Resolution Professional:

The expenses primarily comprised the Erstwhile RP's remuneration along with courier charges for various regulatory communications with BSE, SEBI, and the Registrar and Transfer Agent.

The meeting concluded with all agenda items receiving unanimous approval, reflecting strong committee support for the company's strategic direction and regulatory compliance efforts. The company continues working toward full implementation of the NCLT-approved scheme and resumption of trading activities.